The report of our Chemical Laboratory shows that Saloform is not a definite compound as claimed, but a simple mixture of hexamethylenamin and lithium salicylate. It is therefore in conflict with Rule 1. It is also in conflict with Rule 6, for neither hexamethylenamin, lithium, nor salicylate are therapeutically effective “uric acid solvents”; nor would any of these have any effect on “phosphaturia.” The mixture also conflicts with Rule 10; for it is inadvisable to administer the ingredients in fixed, but unknown proportions. It is recommended that Saloform be deemed inadmissible to N. N. R. The Council adopted the recommendation of the referee and authorized publication of this report.--(_From Reports of Council on Pharmacy and Chemistry, 1916, p. 71._) SECRETOGEN Report of the Council on Pharmacy and Chemistry About a year ago the Council declared Secretogen,[103] a product the active ingredient of which was stated to be “pancreatic secretin” and advertised as a remedy for certain conditions of defective digestion and assimilation, to be ineligible for New and Nonofficial Remedies. The reasons for this decision were stated at the time as follows: [103] J. A. M. A., May 1, 1915, p. 1518. “1. No evidence has been presented that the absence of secretin is a cause of gastro-intestinal diseases. It is usually present, and if not present, as in achylia gastrica, there is evidently some compensating arrangement by which the pancreas is stimulated to perform its regular functions. “2. There is no evidence that secretin in any form is physiologically active when administered by mouth.” Since Secretogen was not the only so-called secretin preparation on the market, and since the use of secretin preparations was recommended by certain writers, notwithstanding the lack of evidence of its value, the Council caused an experimental investigation of the question to be made. This was carried out by Prof. A. J. Carlson of the University of Chicago. No secretin was found in the commercial products examined, namely, Secretogen Tablets, Secretogen Elixir and Duodenin. Furthermore, Carlson’s results[104] confirmed the Council’s previous conclusion as to the inertness of secretin administered by mouth. The Council endorsed Professor Carlson’s findings.[105] [104] Carlson. A. J.; Lebensohn, J. E., and Pearlman, S. J.; Has Secretin a Therapeutic Value? J. A. M. A., Jan. 15, 1916, p. 178. Reports Council on Pharm. and Chem., 1915, p. 98. [105] So-Called Secretin Preparations, J. A. M. A., Jan 15, 1916, p. 208; Reports Council on Pharm. and Chem., 1915, p. 96.